Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

520
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
520
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

692
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
692
Pharmacodynamic Models: Linear Concentration–Effect Model01:15

Pharmacodynamic Models: Linear Concentration–Effect Model

52
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing...
52
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

7.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
7.2K
Hazard Ratio01:12

Hazard Ratio

686
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
686
Methods of Documentation V: CBE01:23

Methods of Documentation V: CBE

1.5K
Charting by Exception, or CBE, is a method of documentation used in healthcare, particularly in nursing, that focuses on documenting only significant or abnormal findings rather than recording every detail. This approach aims to streamline the documentation process, improve efficiency, and ensure that healthcare providers can quickly identify deviations from normalcy in patient assessments.
In CBE, healthcare professionals establish predefined standards of practice that define what constitutes...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond health: a systematic review of cross-sector economic implications of school-based mental health programmes in Europe.

BMJ public health·2026
Same author

Correction: Access to healthcare services and adherence to treatments for people with dementia among ethnic minority groups: a scoping review.

Frontiers in dementia·2026
Same author

Costs of autism spectrum disorders and access to services in Spain.

BMC health services research·2026
Same author

Cost-effectiveness of integrated prevention for late-life depressive symptoms: Real-world findings from a large-scale pragmatic trial ("JoyAge").

Journal of affective disorders·2026
Same author

Association between becoming a carer in later life and changes in the trajectory of cognitive function: results from the English longitudinal study of ageing.

Age and ageing·2026
Same author

Good communication with adults with learning disabilities in long-term care settings: A realist review.

Disability and health journal·2026

Related Experiment Video

Updated: Mar 18, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.5K

The cost-effectiveness challenge: is it worth it?

Martin Knapp1

  • 1Personal Social Services Research Unit, London School of Economics and Political Science, London, WC2A 2AE, UK. m.knapp@lse.ac.uk.

Alzheimer'S Research & Therapy
|July 9, 2016
PubMed
Summary
This summary is machine-generated.

Resource scarcity necessitates difficult choices in healthcare. Cost-effectiveness analysis helps decision-makers achieve best value by comparing interventions and guiding resource allocation for improved health outcomes.

More Related Videos

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

1.0K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

9.3K

Related Experiment Videos

Last Updated: Mar 18, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.5K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

1.0K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

9.3K

Area of Science:

  • Health Economics
  • Decision Science

Background:

  • Healthcare systems face resource scarcity, requiring difficult decisions on intervention allocation.
  • Cost-effectiveness evidence is crucial for maximizing value from limited resources.
  • Interventions often present trade-offs between improved outcomes and increased costs.

Purpose of the Study:

  • To explain how cost-effectiveness evidence aids decision-makers in resource allocation.
  • To illustrate the process of evaluating trade-offs between intervention costs and outcomes.
  • To highlight the role of generic outcome measures in strategic healthcare decisions.

Main Methods:

  • Utilizing cost-effectiveness analysis to compare clinical interventions.
  • Employing generic outcome measures, such as quality-adjusted life years (QALYs).
  • Illustrating decision-making trade-offs with examples from the dementia care field.

Main Results:

  • Cost-effectiveness analysis provides a framework for assessing 'best value' in resource allocation.
  • Decision-makers must weigh the worth of improved outcomes against higher intervention costs.
  • Generic measures like QALYs facilitate strategic comparisons of diverse healthcare interventions.

Conclusions:

  • Cost-effectiveness analysis is essential for optimizing resource use in healthcare.
  • The primary goal of healthcare is to improve and save lives, not solely to reduce costs.
  • Evidence-based decision-making, supported by cost-effectiveness, maximizes health system impact.